PURE EP System Featured in the Journal of Innovations in Cardiac Rhythm Management
Publication Highlights Results Obtained with the PURE EP System in Challenging Recording Situations
Minneapolis, MN, May 09, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4+ billion electrophysiology (EP) marketplace, today announced that the Company’s co-authored manuscript with physicians from Mayo Clinic and Harvard Brigham & Women's Hospital entitled, “Initial Experience with the BioSig PURE EP™ Signal Recording System: An Animal Laboratory Experience” was published in The Journal of Innovations in Cardiac Rhythm Management (JICRM), April 2017 issue.
The manuscript provides a thorough review of many of the ongoing challenges faced in the EP lab using current electrophysiology recording and mapping systems. Initial results and solutions offered by the PURE EP(TM) System are highlighted in several main categories:
- Saturation artifact
- Clipping/Overlapping of signals
- Noise due to ablation
- Unipolar signals
- Contact force
- Poor catheter visualization
- Conduction tissue signal recording
To learn more details about the authors’ findings, please visit the following link to the manuscript in JICRM: http://www.innovationsincrm.com/cardiac-rhythm-management/articles-2017/april/1001-biosig-pure-ep-signal-recording-system
BioSig Executive Chairman, Kenneth Londoner stated, “BioSig is very grateful to collaborate with key opinion leaders in the EP field. This collaboration, together with preclinical data derived from studies conducted from 2015 to date, have produced very significant results to help the Company strengthen its positioning statement for the PURE EP System. The findings in this publication clearly show the need for expanding the boundaries in recording cardiac signals in the electrophysiology lab. Our system demonstrated abilities to produce great recordings from legacy catheters (Boston Scientific and Johnson & Johnson) and enhanced recordings compared to existing recording and mapping systems. One of the most important findings is PURE EP System’s ability to record high quality unipolar signals and current of injury (COI) which can complement data obtained using a contact force-sensing catheter. We are very excited about these initial results and our future direction.”
The Journal of Innovations in Cardiac Rhythm Management has been in continuous publication since 2010, is an international open access double blind peer-reviewed clinical journal published 12 times per year.
JICRM is a widely circulated journal on the latest developments impacting the field of cardiac arrhythmia management, including advancements in device therapy and evolutions within electrophysiology in the world. The print and online version is made freely available.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance and CE Mark for the PURE EP System.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Relations: Lora Mikolaitis BioSig Technologies, Inc. firstname.lastname@example.org 310.948.7200
Released May 9, 2017